- Home
- APLT vs CGEN Comparison
APLT vs CGEN Comparison
Compare APLT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- CGEN
- Stock Information
- Founded
- APLT 2016
- CGEN 1993
- Country
- APLT United States
- CGEN Israel
- Employees
- APLT N/A
- CGEN N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLT Health Care
- CGEN Health Care
- Exchange
- APLT Nasdaq
- CGEN Nasdaq
- Market Cap
- APLT 128.0M
- CGEN 142.4M
- IPO Year
- APLT 2019
- CGEN 2000
- Fundamental
- Price
- APLT $0.65
- CGEN $2.25
- Analyst Decision
- APLT Buy
- CGEN Strong Buy
- Analyst Count
- APLT 7
- CGEN 1
- Target Price
- APLT $6.10
- CGEN $4.00
- AVG Volume (30 Days)
- APLT 7.5M
- CGEN 898.9K
- Earning Date
- APLT 03-05-2025
- CGEN 03-04-2025
- Dividend Yield
- APLT N/A
- CGEN N/A
- EPS Growth
- APLT N/A
- CGEN N/A
- EPS
- APLT N/A
- CGEN 0.02
- Revenue
- APLT N/A
- CGEN $59,852,000.00
- Revenue This Year
- APLT N/A
- CGEN $57.27
- Revenue Next Year
- APLT $2,622.90
- CGEN N/A
- P/E Ratio
- APLT N/A
- CGEN $125.59
- Revenue Growth
- APLT N/A
- CGEN 698.03
- 52 Week Low
- APLT $0.60
- CGEN $1.35
- 52 Week High
- APLT $10.62
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- APLT 20.60
- CGEN 81.70
- Support Level
- APLT $0.60
- CGEN $1.92
- Resistance Level
- APLT $0.74
- CGEN $2.16
- Average True Range (ATR)
- APLT 0.09
- CGEN 0.15
- MACD
- APLT 0.21
- CGEN 0.07
- Stochastic Oscillator
- APLT 13.53
- CGEN 88.90
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.